MedTrace Logo

A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy

NCT01728298 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2014-01-22

No results posted yet for this study

Summary

The primary objective of the trial is to evaluate the dose-response relationship with regards to change in immunological parameters and safety for SLITone ULTRA house dust mite mix in adult subjects with moderate to severe HDM allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

SLITone ULTRA HDM immunotherapy

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Alain Didier, Pr. · Hôpital Larrey, Toulouse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01728298 on ClinicalTrials.gov